Phase I study of alpha-galactosylceramide-pulsed antigen presenting cells administration to the nasal submucosa in unresectable or recurrent head and neck cancer.
BACKGROUND
Human Valpha24 natural killer T (NKT) cells are activated by the specific ligand, alpha-galactosylceramide (alpha-GalCer), in a CD1d-dependent manner. Potent anti-tumor activity of activated NKT cells has been previously demonstrated.


METHODS
We conducted a phase I study with alpha-GalCer-pulsed antigen presenting cells (APCs) administered in the nasal submucosa of patients with head and neck cancer, and evaluated the safety and feasibility of such a treatment. Nine patients with unresectable or recurrent head and neck cancer received two treatments 1 week apart, of 1 x 10(8) of alpha-GalCer-pulsed autologous APCs into the nasal submucosa.


RESULTS
During the clinical study period, no serious adverse events (Common Terminology Criteria for Adverse Events version 3.0 greater than grade 3) were observed. After the first and the second administration of alpha-GalCer-pulsed APCs, an increased number of NKT cells was observed in four patients and enhanced natural killer activity was detected in the peripheral blood of eight patients.


CONCLUSIONS
The administration of alpha-GalCer-pulsed APCs into the nasal submucosa was found to be safe and induce anti-tumor activity in some patients.
Uchida
Tetsuro
T
Department of Immunology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Horiguchi
Shigetoshi
S
Tanaka
Yuriko
Y
Yamamoto
Heizaburo
H
Kunii
Naoki
N
Motohashi
Shinichiro
S
Taniguchi
Masaru
M
Nakayama
Toshinori
T
Okamoto
Yoshitaka
Y
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000938:Antigen-Presenting Cells / Q000276:immunology / Q000637:transplantation*; D002478:Cells, Cultured; D005260:Female; D005699:Galactosylceramides / Q000494:pharmacology*; D006258:Head and Neck Neoplasms / Q000175:diagnosis / Q000276:immunology / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D007371:Interferon-gamma / Q000096:biosynthesis / Q000276:immunology; D007694:Killer Cells, Natural / Q000276:immunology; D007963:Leukocytes, Mononuclear / Q000187:drug effects* / Q000276:immunology; D017710:Lymphocyte Transfusion / Q000009:adverse effects / Q000379:methods*; D008297:Male; D008875:Middle Aged; D009297:Nasal Mucosa / Q000276:immunology*; D010641:Phenotype; D012008:Recurrence; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
D005699:Galactosylceramides; C493154:alpha-galactosylceramide; D007371:Interferon-gamma
Eur J Immunol. 2000 Jul;30(7):1919-28
10940881
J Exp Med. 2000 Jan 3;191(1):105-14
10620609
Annu Rev Immunol. 2004;22:817-90
15032598
Annu Rev Immunol. 1999;17:297-329
10358761
J Exp Med. 2003 Jul 21;198(2):267-79
12874260
Int J Cancer. 2002 Nov 10;102(2):159-65
12385012
J Clin Invest. 2004 Nov;114(10):1379-88
15545985
J Clin Oncol. 2000 Feb;18(4):904-14
10673534
Eur J Immunol. 1999 Aug;29(8):2406-13
10458753
Eur J Immunol. 2000 Apr;30(4):985-92
10760785
J Exp Med. 2005 May 2;201(9):1503-17
15867097
Clin Cancer Res. 2005 Mar 1;11(5):1910-7
15756017
J Leukoc Biol. 2006 Feb;79(2):268-76
16330534
Clin Cancer Res. 2002 Dec;8(12):3702-9
12473579
J Clin Oncol. 2006 Sep 1;24(25):4163-9
16943532
Nat Immunol. 2001 Apr;2(4):293-9
11276199
Blood. 2004 Jan 15;103(2):383-9
14512316
Int J Cancer. 2005 Nov 1;117(2):265-73
15900581
Expert Opin Emerg Drugs. 2006 Sep;11(3):461-7
16939385
J Laryngol Otol. 1996 May;110(5):449-53
8762314
J Immunol. 2005 Sep 1;175(5):3309-17
16116223
Nat Rev Immunol. 2004 Mar;4(3):231-7
15039760
Blood. 2002 Feb 15;99(4):1259-66
11830474
J Immunol. 1999 Nov 1;163(9):4647-50
10528160
Nat Rev Immunol. 2003 Mar;3(3):211-22
12658269
J Clin Oncol. 2005 Aug 20;23(24):5568-77
16009950
Clin Otolaryngol. 2005 Aug;30(4):303-19
16209671
J Immunol. 2003 Oct 15;171(8):4020-7
14530322
Annu Rev Immunol. 1997;15:535-62
9143699
J Exp Med. 2005 Jun 20;201(12):1973-85
15967825
Cancer Sci. 2006 Sep;97(9):807-12
16805854
Annu Rev Immunol. 2003;21:483-513
12543936
Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6079-86
17028247
Int Immunol. 2004 Feb;16(2):241-7
14734609